Magnitude and Temporal Variations of Socioeconomic Inequalities in the Quality of Life After Early Breast Cancer: Results From the Multicentric French CANTO Cohort.


Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333

Informations de publication

Date de publication:
18 Jun 2024
Historique:
medline: 18 6 2024
pubmed: 18 6 2024
entrez: 18 6 2024
Statut: aheadofprint

Résumé

Socioeconomic status (SES) influences the survival outcomes of patients with early breast cancer (EBC). However, limited research investigates social inequalities in their quality of life (QoL). This study examines the socioeconomic inequalities in QoL after an EBC diagnosis and their time trends. We used data from the French prospective multicentric CANTO cohort (ClinicalTrials.gov identifier: NCT01993498), including women with EBC enrolled between 2012 and 2018. QoL was assessed using the European Organisation for Research and Treatment of Cancer QoL Core 30 questionnaire (QLQ-C30). summary score at diagnosis and 1 and 2 years postdiagnosis. We considered three indicators of SES separately: self-reported financial difficulties, household income, and educational level. We first analyzed the trajectories of the QLQ-C30 summary score by SES group. Then, social inequalities in QLQ-C30 summary score and their time trends were quantified using the regression-based slope index of inequality (SII), representing the absolute change in the outcome along socioeconomic gradient extremes. The analyses were adjusted for age at diagnosis, Charlson Comorbidity Index, disease stage, and type of local and systemic treatment. Among the 5,915 included patients with data on QoL at diagnosis and at the 2-year follow-up, social inequalities in QLQ-C30 summary score at baseline were statistically significant for all SES indicators (SII The magnitude of preexisting inequalities in QoL increased over time after EBC diagnosis, emphasizing the importance of considering social determinants of health during comprehensive cancer care planning.

Identifiants

pubmed: 38889372
doi: 10.1200/JCO.23.02099
doi:

Banques de données

ClinicalTrials.gov
['NCT01993498']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

JCO2302099

Auteurs

José Luis Sandoval (JL)

Unit of Population Epidemiology, Division of Primary Care, Department of Health and Community Medicine, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Division of Oncology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.

Maria Alice Franzoi (MA)

Unit of Molecular Predictors and New Targets in Oncology, INSERM, Gustave Roussy Institute, University Paris Saclay, Villejuif, France.

Antonio di Meglio (A)

Unit of Molecular Predictors and New Targets in Oncology, INSERM, Gustave Roussy Institute, University Paris Saclay, Villejuif, France.
Medical Oncology Department, Gustave Roussy Institute, Villejuif, France.

Arlindo R Ferreira (AR)

Universidade Católica Portuguesa, Lisbon, Portugal.

Alessandro Viansone (A)

Medical Oncology Department, Gustave Roussy Institute, Villejuif, France.

Fabrice André (F)

Unit of Molecular Predictors and New Targets in Oncology, INSERM, Gustave Roussy Institute, University Paris Saclay, Villejuif, France.
Medical Oncology Department, Gustave Roussy Institute, Villejuif, France.

Anne-Laure Martin (AL)

UNICANCER, Direction des Data et des Partenariats, Le Kremlin-Bicêtre, France.

Sibille Everhard (S)

UNICANCER, Direction des Data et des Partenariats, Le Kremlin-Bicêtre, France.

Christelle Jouannaud (C)

Institut Godinot, Reims, France.

Marion Fournier (M)

Institut Bergonié, Bordeaux, France.

Philippe Rouanet (P)

Institut régional du Cancer de Montpellier-Val d'Aurelle, Montpellier, France.

Laurence Vanlemmens (L)

Centre Oscar Lambret, Lille, France.

Asma Dhaini-Merimeche (A)

Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandoeuvre lès Nancy, France.

Baptiste Sauterey (B)

Institut de Cancérologie de L'ouest-Site Angers, Angers, France.

Paul Cottu (P)

Institut Curie, Paris, France.

Christelle Levy (C)

Centre François Baclesse, Caen, France.

Silvia Stringhini (S)

Unit of Population Epidemiology, Division of Primary Care, Department of Health and Community Medicine, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Idris Guessous (I)

Unit of Population Epidemiology, Division of Primary Care, Department of Health and Community Medicine, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Ines Vaz-Luis (I)

Unit of Molecular Predictors and New Targets in Oncology, INSERM, Gustave Roussy Institute, University Paris Saclay, Villejuif, France.
Interdisciplinary department for the Organization of Patient Pathways (DIOPP), Gustave Roussy Institute, Villejuif, France.

Gwenn Menvielle (G)

Unit of Molecular Predictors and New Targets in Oncology, INSERM, Gustave Roussy Institute, University Paris Saclay, Villejuif, France.

Classifications MeSH